All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
How should we treat smoldering myeloma?
Bookmark this article
The Multiple Myeloma Hub are pleased to present a series of expert interviews from the 61st American Society of Hematology (ASH) meeting in Orlando, US. In this video, Irene Ghobrial, Dana-Farber Cancer Institute, Boston, US, answers the question: How should we treat smoldering myeloma?
Professor (Prof.) Ghobrial discusses the often debated topic of whether we should or should not treat smoldering multiple myeloma (SMM). Prof. Ghobrial argues in favor of treating SMM, but highlights it is important to select the right patients for treatment to avoid over-treatment. Additionally, Prof. Ghobrial discusses new options for treating SMM as presented during the ASH meeting such as daratumumab monotherapy for low-risk SMM, and different approaches using biomarkers and cytogenetic information.
How should we treat smoldering myeloma?
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox